Cost‐of‐illness study for axillary hyperhidrosis in Japan
Autor: | Hiroyuki Murota, Sachie Inoue, Hiromichi Okatsu, Naoya Murayama, Yasuhiko Tamada, Tomoko Fujimoto, Takeshi Yanagishita, Yuichiro Oshima, Hiroshi Miyama, Hiroo Yokozeki |
---|---|
Rok vydání: | 2021 |
Předmět: |
Adult
Male Pediatrics medicine.medical_specialty Adolescent Total cost media_common.quotation_subject Population cost of illness Dermatology Axillary hyperhidrosis Young Adult Japan Hygiene medicine Cost of illness Health insurance Humans Hyperhidrosis Botulinum Toxins Type A education Productivity health care economics and organizations media_common Work productivity education.field_of_study business.industry Original Articles General Medicine Middle Aged Cross-Sectional Studies self‐medication cost axillary hyperhidrosis Axilla direct medical cost Female Original Article overall work impairment business |
Zdroj: | The Journal of Dermatology |
ISSN: | 1346-8138 0385-2407 |
Popis: | The prevalence of primary axillary hyperhidrosis in Japan is 5.75% (males, 6.60%; females, 4.72%) in the population aged 5–64 years. No study on comprehensively evaluated direct medical costs, hygiene product costs, and productivity loss in axillary hyperhidrosis patients has been published in Japan. The aim of this study was to estimate the cost of illness for axillary hyperhidrosis in Japan by conducting a nationwide insurance claims database analysis and a cross‐sectional Web‐based survey. Among patients diagnosed with primary axillary hyperhidrosis at least once between November 2012 and October 2019, health insurance receipt data of 1447 patients were analyzed. A cross‐sectional Web‐based survey was conducted on 321 patients aged 16–59 years with axillary hyperhidrosis to calculate hygiene product costs and productivity loss using a Work Productivity and Activity Impairment questionnaire. Furthermore, nationwide estimation was performed for the hygiene product costs and productivity loss based on the number of patients estimated from the prevalence. The annual direct medical costs per axillary hyperhidrosis patient were ¥91 491 in 2016, ¥93 155 in 2017, and ¥75 036 in 2018. In all of these years, botulinum toxin type A injection accounted for approximately 90% of the total costs. The annual total cost of hygiene products per axillary hyperhidrosis patient was ¥9325. The overall work impairment (%) of working patients with axillary hyperhidrosis was 30.52%, and its monthly productivity loss was ¥120 593/patient. The activity impairment (%) of full‐time housewives with axillary hyperhidrosis was 49.05% and its monthly productivity loss was ¥176 368/patient. The annual hygiene product cost based on the nationwide estimation was ¥24.5 billion and the monthly productivity loss was ¥312 billion. The significant cost associated with axillary hyperhidrosis was clarified. If out‐of‐pocket expenses for treatments not covered by health insurance are included in the estimation, the cost will further increase. |
Databáze: | OpenAIRE |
Externí odkaz: |